Skip to main content

Table 4 Multivariate analysis by Cox proportional hazards regression model and diagnostic accuracy of 180-day mortality

From: Pentraxin-3 as a marker of disease severity and risk of death in patients with necrotizing soft tissue infections: a nationwide, prospective, observational study

Markers

180-day mortality

 

HRa

95 % CI

p

Sensitivity

95 % CI

Specificity

95 % CI

ROC-AUC

95 % CI

p

PTX3

1.05

0.47–2.35

0.902

0.69

0.53–0.82

0.56

0.50–0.60

0.66

0.56–0.76

0.005

PTX3b

1.34

0.60–3.00

0.480

0.67

0.51–0.80

0.68

0.62–0.72

.

.

.

PCT

0.86

0.38–1.95

0.713

0.66

0.50–0.79

0.55

0.49–0.60

0.65

0.55–0.76

0.007

CRP

0.71

0.34–1.51

0.376

0.34

0.21–0.50

0.41

0.36–0.47

0.32

0.21–0.43

0.001

PTX3 + PCT

.

.

.

.

.

.

.

0.66

0.56–0.76

0.005

PTX3 + CRP

.

.

.

.

.

.

.

0.72

0.61–0.82

<0.0001

PCT + CRP

.

.

.

.

.

.

.

0.71

0.60–0.82

<0.0001

PTX3 + PCT + CRP

.

.

.

.

.

.

.

0.72

0.62–0.83

<0.0001

  1. Hazard ratio, sensitivity and specificity are calculated for high (above median) versus low (below median) baseline levels of the inflammatory biomarkers. Five patients are not included in the analysis due to missing data regarding Simplified Acute Physiology Score II
  2. aAdjusted for age, sex, Simplified Acute Physiology Score II and chronic disease (yes/no)
  3. bPTX3 dichotomized by the optimal cutoff (69.8 ng/ml) found by the ROC curve (highest sum of sensitivity and specificity)
  4. CRP C-reactive protein, HR Hazard ratio, PCT Procalcitonin, PTX3 Pentraxin-3, ROC-AUC Receiver operating characteristic-area under the curve, CI Confidence interval
  5. Dots: Values cannot be given
Back to article page

Critical Care

ISSN: 1364-8535